drugset / Trial / NCT01114893

Travoprost Five Day Posology Study

NCT01114893

Phase 2 Completed 60 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.

Timeline

Start
2010-04
Primary completion
2010-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Travoprost Other / unclassified 0.004 % Topical